Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020109316 - METHODS FOR DIAGNOSING AND/OR TREATING ACUTE OR CHRONIC LIVER, KIDNEY OR LUNG DISEASE

Publication Number WO/2020/109316
Publication Date 04.06.2020
International Application No. PCT/EP2019/082606
International Filing Date 26.11.2019
IPC
A61K 31/4365 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4365the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/713 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 13/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61K 31/427 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
CPC
A61K 31/427
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
A61K 31/4365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4365the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/713
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
Applicants
  • ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE [ES]/[ES]
Inventors
  • SIMÓN, Jorge
  • MARTÍNEZ CHANTAR, María Luz
  • MARTÍNEZ DE LA CRUZ, Alfonso
Agents
  • ABG INTELLECTUAL PROPERTY LAW, S.L.
Priority Data
18382853.226.11.2018EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR DIAGNOSING AND/OR TREATING ACUTE OR CHRONIC LIVER, KIDNEY OR LUNG DISEASE
(FR) PROCÉDÉS DE DIAGNOSTIC ET/OU DE TRAITEMENT D'UNE MALADIE HÉPATIQUE, RÉNALE OU PULMONAIRE AIGUË OU CHRONIQUE
Abstract
(EN)
The present invention relates to a CNNM4 inhibitor for use in the treatment of an acute or a chronic liver, kidney and/or lung disease in a subject, and to pharmaceutical compositions comprising a therapeutically effective amount of a CNNM4 inhibitor and a pharmaceutically acceptable excipient or carrier. Furthermore, the invention relates to a method for diagnosing a liver disease, a kidney disease or a lung disease in a subject, and to in vitro methods for identifying a compound potentially useful for reducing an induced CNNM4-mediated disease or condition in a cell.
(FR)
La présente invention concerne un inhibiteur de CNNM4 destiné à être utilisé dans le traitement d'une maladie hépatique, rénale et/ou pulmonaire aiguë ou chronique chez un sujet, et des compositions pharmaceutiques comprenant une quantité thérapeutiquement efficace d'un inhibiteur de CNNM4 et un excipient ou un vecteur pharmaceutiquement acceptable. En outre, l'invention concerne un procédé de diagnostic d'une maladie hépatique, d'une maladie rénale ou d'une maladie pulmonaire chez un sujet, et des procédés in vitro pour identifier un composé potentiellement utile afin de réduire une maladie ou un état induit médié par CNNM4 dans une cellule.
Latest bibliographic data on file with the International Bureau